The clinical trial landscape of bispecific antibodies in non-small cell lung cancer: mechanistic trends and developmental strategies
Background Non-small cell lung cancer (NSCLC) management remains constrained by acquired resistance to targeted therapies and refractoriness to immune checkpoint inhibitors (ICIs), the latter driven largely by the immunosuppressive tumor microenvironment (TME). Bispecific antibodies (bsAbs) represent a promising modali...